Skip to main content
Clinical Trials/NCT02145676
NCT02145676
Terminated
Phase 3

OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity

Allergan0 sites53 target enrollmentMay 2014

Overview

Phase
Phase 3
Intervention
onabotulinumtoxinA
Conditions
Muscle Spasticity
Sponsor
Allergan
Enrollment
53
Primary Endpoint
Change From Baseline in the Modified Ashworth Scale-Bohannon (MAS-B) Score of Elbow Flexors Using a 6-Point Scale
Status
Terminated
Last Updated
9 years ago

Overview

Brief Summary

This is a safety and efficacy study of onabotulinumtoxinA in poststroke patients with upper limb spasticity.

Registry
clinicaltrials.gov
Start Date
May 2014
End Date
December 2015
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Allergan
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Upper limb spasticity in the elbow and shoulder due to stroke, with the most recent stroke at least 3 months ago

Exclusion Criteria

  • Spasticity in the non-study upper limb that requires treatment
  • Presence of fixed contractures in of the study muscles in elbow or shoulder
  • Profound atrophy of muscles to be injected
  • Previous surgical intervention, nerve block, or muscle block for the treatment of spasticity in the study limb in the last 12 months
  • Injection of corticosteroids or anesthetics, use of casting or dynamic splinting or constraint-induced movement therapy (CIMT) for the study limb within 3 months
  • Ultrasound therapy, electrical stimulation, or acupuncture in the study limb within 1 month
  • Condition other than stroke contributing to upper limb spasticity
  • Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, and/or amyotrophic lateral sclerosis

Arms & Interventions

onabotulinumtoxinA 500U

OnabotulinumtoxinA 500U injected into predefined muscles of the study limb on Day 1.

Intervention: onabotulinumtoxinA

onabotulinumtoxinA 300U

OnabotulinumtoxinA 300U injected into predefined muscles of the study limb on Day 1.

Intervention: onabotulinumtoxinA

placebo (normal saline)

Placebo (normal saline) injected into predefined muscles of the study limb on Day 1.

Intervention: placebo (normal saline)

Outcomes

Primary Outcomes

Change From Baseline in the Modified Ashworth Scale-Bohannon (MAS-B) Score of Elbow Flexors Using a 6-Point Scale

Time Frame: Baseline, Week 6

The MAS-B is a 6-point scale used to evaluate spasticity based on grading the resistance encountered in the elbow flexors by passively moving the elbow flexor muscles through their range of motion. The score ranges from 0 (no increase in muscle tone) to 4 (affected part(s) rigid in flexion or extension). Scores are converted to a 0 to 5 grade. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.

Secondary Outcomes

  • Change From Baseline in the MAS-B Score of Shoulder Adductors Using a 6-Point Scale(Baseline, Week 6)
  • Change From Baseline in Pain on an 11-Point Scale(Baseline, Week 6)
  • Change From Baseline in the Dressing Domain Score on the Spasticity Impact Assessment-Upper Limb (SIA-UL)(Baseline, Week 6)
  • Change From Baseline in the Showering/Bathing Domain Score on the Spasticity Impact Assessment-Upper Limb (SIA-UL)(Baseline, Week 6)
  • Change From Baseline in the Self-Care Domain Score on the Spasticity Impact Assessment-Upper Limb (SIA-UL)(Baseline, Week 6)

Similar Trials